ModifiedUnitedHealthcarePolicy CSLA2025D0036V

Somatostatin Analogs (for Louisiana Only)

A UnitedHealthcare Medical Benefit Drug Policy governing coverage criteria for somatostatin analog medications (e.g., octreotide, lanreotide, pasireotide) for members in Louisiana.

Policy Summary

PayerUnitedHealthcare

PolicySomatostatin Analogs (for Louisiana Only)

Policy CodePolicy CSLA2025D0036V

Change TypeCoverage stance updatedHIV-AIDS-related diarrhea removed as proven

Effective DateJun 1, 2025

Next Review DateN/A

Key ActionSubmit prior authorization with diagnostic confirmation and documentation of prior short‑acting response when requesting long‑acting somatostatin analogs.

SourceLink

POLICY UPDATE CHANGES

Added language to indicate Somatostatin analogs are unproven and not medically necessary for treating HIV-AIDS-related diarrhea.

Removed language indicating Sandostatin and Sandostatin LAR are proven for the treatment of refractory HIV/AIDS-related diarrhea.

Removed ICD-10 diagnosis codes B20 and R19.7 from the policy.

Retired policy for Louisiana plan membership disenrolled on Apr. 1, 2026.

Updated Clinical Evidence, FDA, and References sections to reflect the most current information.

multipleApplicable J-codes referenced

state-specificApplies to

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

10+ indicationsEvidence summaries

highPasireotide hyperglycemia rates

Coverage Criteria

Bleeding Gastroesophageal Varices

Covered when ALL of the following are met:

ALL of the following

Diagnosis of bleeding esophageal varices associated with liver disease.
Octreotide acetate (Sandostatin or Sandostatin LAR) will be used as an adjunct to endoscopic therapy.

Chemotherapy-/Radiation-Induced Diarrhea and Malignant Bowel Obstruction

Covered (proven) for the following indications:

ANY of the following

Chemotherapy- or radiation-induced diarrhea.
Malignant bowel obstruction (symptomatic malignant bowel disease).

Acromegaly — Immediate-Release Octreotide

Covered when ALL of the following are met:

ALL of the following

Diagnosis of acromegaly.
Diagnosis has been confirmed by one of the following: serum GH level > 1 ng/mL after a 2-hour oral glucose tolerance test (OGTT) at time of diagnosis; or elevated serum IGF-1 level above the age- and gender-adjusted normal range at time of diagnosis.
AND one of the following:
- Inadequate response to surgery, radiotherapy, or a dopamine agonist (e.g., bromocriptine, cabergoline).
- Not a candidate for surgery, radiotherapy, and dopamine agonist therapy.

Acromegaly — Long-Acting Somatostatin Analogs (Sandostatin LAR, Signifor LAR, Somatuline Depot, Lanreotide Injection)

Covered when ALL of the following are met:

ALL of the following

Diagnosis of acromegaly.
Diagnosis has been confirmed by one of the following: serum GH level > 1 ng/mL after a 2-hour OGTT at time of diagnosis; or elevated serum IGF-1 level above the age- and gender-adjusted normal range at time of diagnosis.

Cushing's Disease — Pasireotide (Signifor / Signifor LAR)

Covered when BOTH of the following are met:

ALL of the following

Diagnosis of Cushing's disease.
ANY of the following
- Inadequate response to pituitary surgery.
- Not a candidate for pituitary surgery.

Formulation-Specific: Sandostatin LAR

Formulation-specific indication — Sandostatin LAR is covered when ALL of the following are met:

ALL of the following

Patient has been shown to tolerate and respond to initial treatment with Sandostatin subcutaneous (immediate-release) injection prior to transition to Sandostatin LAR.
Indication corresponds to an FDA-labeled use for the long-acting formulation (e.g., long-term maintenance therapy for acromegaly after response to short-acting octreotide; long-term treatment of carcinoid syndrome or VIPoma-associated diarrhea).

Pasireotide (Signifor) Clinical Rationale

Pasireotide (Signifor / Signifor LAR) clinical rationale:

Pasireotide binds multiple somatostatin receptor subtypes (including SSTR5) and can reduce ACTH and cortisol secretion in patients with Cushing's disease; it is indicated for adults for whom pituitary surgery is not an option or has not been curative. Use requires consideration of substantial risk of hyperglycemia and monitoring of glycemic parameters.

Bleeding Gastroesophageal Varices — Adjunctive Use

Covered when ALL of the following are met:

ALL of the following

Diagnosis of bleeding gastroesophageal varices associated with liver disease.
Octreotide (short-acting or long-acting) will be used as an adjunct to endoscopic therapy (e.g., sclerotherapy, banding).
Evidence supports improved initial control of bleeding and reduced early rebleeding when combined with endoscopic techniques; mortality benefits are not clearly established.

Chemotherapy-/Radiation-Induced Diarrhea and Malignant Bowel Obstruction — Clinical Considerations

Clinical coverage considerations:

ANY of the following

Octreotide is recommended early for symptomatic management of malignant bowel obstruction as an antisecretory/antiflux agent; corticosteroids and other supportive measures are commonly used concomitantly.
For chemotherapy- or radiation-induced diarrhea, octreotide is an accepted second-line agent when loperamide and other first-line measures fail; radiation-induced diarrhea response may be variable and requires clinical judgment.

Not Medically Necessary / Unproven Indications

Not medically necessary / Unproven:

ANY of the following

HIV-AIDS-related diarrhea — somatostatin analogs are unproven and not medically necessary for this indication per policy update; prior medical necessity criteria for refractory HIV/AIDS-related diarrhea have been removed.
Chylothorax — use in neonates, children, and adults is unproven; randomized controlled trial evidence is lacking and no formal practice recommendation can be made.
Dumping syndrome — short-term symptom control is demonstrated but long-term benefit is limited by side effects; considered unproven for routine long-term therapy.
Pancreatitis — routine use of somatostatin or octreotide for acute pancreatitis or prophylactic use for ERCP-related pancreatitis is not recommended due to conflicting and unconvincing data; evidence does not support routine prophylactic octreotide or gabexate mesilate for ERCP-related prevention.

Coding — Applicable Codes and Mappings

Applicable J-codesHCPCS

J1930	Injection, lanreotide, 1 mg.
J1932	Injection, lanreotide, (cipla), 1 mg.
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg.
J2354	Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg.
J2502	Injection, pasireotide long acting, 1 mg

Mapped ICD-10 Diagnosis Codes used for billing referenceICD-10

C17.0 - C17.9	Malignant neoplasm of small intestine (various)
C18.0 - C18.9	Malignant neoplasm of colon (various)
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21.0 - C21.8	Malignant neoplasm of anus/anal canal (various)
C25.0 - C25.9	Malignant neoplasm of pancreas (various)
C7A.010 - C7A.095	Malignant carcinoid tumors (various sites)

Applicable HCPCS/J-codes listed with diagnosesHCPCS

J1930	Injection, octreotide, 1 mcg (example listed as used with many diagnoses)
J1932	Injection, octreotide (long-acting) (example listed)
J2353	Injection, lanreotide (example listed)
J2354	Injection, lanreotide (alternate) (example listed)
J2502	Injection, pasireotide (example listed)

Applicable ICD-10 Diagnosis CodesICD-10

C7A.010	Malignant carcinoid tumor of the duodenum
C7A.011	Malignant carcinoid tumor of the jejunum
C7A.012	Malignant carcinoid tumor of the ileum
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion
C7A.020	Malignant carcinoid tumor of the appendix
C7A.021	Malignant carcinoid tumor of the cecum
C7A.022	Malignant carcinoid tumor of the ascending colon
C7A.024	Malignant carcinoid tumor of the descending colon
C7A.025	Malignant carcinoid tumor of the sigmoid colon
C7A.026	Malignant carcinoid tumor of the rectum

1–10 of 26

1/3

Applicable ICD-10 / HCPCS codes (reformatted)mixed

No codes listed

GH suppression on OGTT — Serum GH > 1 ng/mL after 2-hour OGTT at time of diagnosis

CriterionSerum GH level > 1 ng/mL after a 2-hour OGTT at time of diagnosis

TimingMeasured at time of diagnosis during 2-hour OGTT

ApplicationUsed as part of documentation to justify coverage of octreotide IR and LAR for acromegaly

octreotide total dosage for ERCP prevention — >= 0.5 mg

Dose threshold>= 0.5 mg total octreotide (cumulative) associated with preventive efficacy in some analyses

Evidence source

Provider Actions and Requirements

Prior Authorization

Prior Authorization for Injectable Formulations

Prior authorization is required per the Medical Benefit Drug Policy for long‑acting and injectable somatostatin analog formulations. Requests must include the specific HCPCS/J‑code being billed, the associated ICD‑10 diagnosis, and documentation that the requested formulation and route are appropriate for the diagnosis and patient.

Affected HCPCS (examples): J1930, J1932, J2353, J2354, J2502.
Prior authorization surrogates and benefit‑plan rules apply — follow UnitedHealthcare standard prior authorization processes.

Documentation Required

Biochemical Evidence and Prior Therapy for LAR Agents

For long‑acting (LAR/Depot) somatostatin analogs, documentation must include biochemical confirmation of the diagnosis (see diagnostic criteria below) and evidence of prior therapy as applicable (surgery, radiotherapy, or dopamine agonist), or documentation that the patient is not a candidate for those options.

For acromegaly: confirmatory testing (OGTT with nadir GH > 1 ng/mL OR elevated age‑/sex‑adjusted IGF‑1).

Initial Therapy Criteria

inv-70: Initial IR treatment — Initial treatment note

Initial treatment note

IR initial treatment: Initial treatment with octreotide immediate release (IR) has been shown to be effective and tolerated and is noted as an initial therapy prior to some long-acting formulations.

Document IR response when used as a trial before LAR formulations.

inv-71: Initial short-acting trial requirement — Initial use / trial before LAR

Initial use / trial before LAR

Initial short-acting trial: Sandostatin LAR should be used in patients who have demonstrated efficacy and tolerability with immediate-release Sandostatin injection prior to initiation of LAR; documentation of prior response is required.

LAR is indicated for patients in whom initial treatment with Sandostatin injection has been shown to be effective and tolerated; LAR given IM every 4 weeks under physician supervision.

Continuation and Maintenance Criteria

inv-74: Continuation to long-acting formulation — Long-acting formulations continuation rules

Long-acting formulations continuation rules

Continuation to LAR: Sandostatin LAR, Somatuline Depot, and Lanreotide Injection are indicated for long-term maintenance in acromegalic patients who had an adequate trial with short-acting formulation or who had inadequate response to or cannot be treated with surgery/radiotherapy; continue LAR per product labeling with documentation of prior short-acting response or indication for long-term therapy.

LAR dosing schedules and administration setting (IM intragluteal or deep SC) must be documented; continuation requires evidence of clinical or biochemical benefit.

inv-75: Pasireotide continuation — Long-term continuation considerations for pasireotide

Long-term continuation considerations for pasireotide:

Long-term pasireotide continuation: Patients with normalized urinary free cortisol or clear clinical benefit at month 12 may continue pasireotide; sustained reductions were observed in subsets up to 60 months. Monitor for hyperglycemia and manage accordingly when continuing therapy long-term.

Step Therapy Requirements

Requirement	Notes
Documentation of inadequate response to prior therapies or documentation that patient is not a candidate for those therapies	Policy requires either inadequate response to surgery, radiotherapy, or dopamine agonist therapy, or documentation that the patient is not a candidate for these treatments before use of long-acting formulations (LAR).

Requirement	Notes
Trial and documented clinical response to immediate‑release (IR) Sandostatin (octreotide) prior to Sandostatin LAR	Sandostatin LAR is indicated for patients in whom initial treatment with Sandostatin injection has been shown to be effective and tolerated; LAR is given IM (intragluteal) every 4 weeks under physician supervision.

Step	Action
Add pegvisomant	Endocrine guideline recommendation: add pegvisomant for inadequate response to a somatostatin analogue.
Add cabergoline	Endocrine guideline recommendation: add cabergoline as an option for patients with inadequate response to an SRL.

Situation	Recommended step/add‑on
Inadequate biochemical response to a somatostatin analogue (SRL)	Add pegvisomant or cabergoline; consider combination SRL + pegvisomant for improved biochemical control (combination is cost‑effective and efficacious).
Patients uncontrolled on SRL and candidate for intensified therapy	Consider combination of pasireotide plus pegvisomant in select patients (can achieve >70% biochemical control) but carefully consider patient selection due to pasireotide‑related hyperglycemia risk.

Site of Care

Note

Administer LAR intramuscular injections under physician supervision

Long‑acting intramuscular (LAR) injections are designed to be administered intramuscularly (intragluteal) once every 4 weeks and must be given under physician supervision.

Sandostatin LAR: injected intramuscularly (intragluteally) once every 4 weeks and must be administered under the supervision of a physician.

Note

Administer long‑acting injectables in outpatient clinic/infusion settings

Long‑acting injectable formulations are administered in outpatient settings (clinic or specialty infusion/injection centers) per trial administration schedules (every 28 days for LAR formulations).

Policy site‑of‑care guidance specifies outpatient clinic or specialty infusion/injection center administration for long‑acting formulations.

Note

Administer depot injections in outpatient/clinic per product labeling

Background

Somatostatin analogs (octreotide, lanreotide, pasireotide) are a pharmacologic class used to manage hormone‑secreting tumors and related symptoms. They have both immediate‑release and long‑acting depot formulations (e.g., Sandostatin, Sandostatin LAR, Somatuline Depot, Signifor/Signifor LAR). These agents are employed for conditions such as acromegaly, Cushing's disease (pasireotide), carcinoid syndrome and malignant bowel disease, and as adjunctive therapy for bleeding varices. Product labeling and clinical evidence guide indication‑specific use and monitoring.

Definitions and Clinical Thresholds

Acromegaly diagnostic confirmation

DefinitionEither serum GH > 1 ng/mL after a 2-hour oral glucose tolerance test (OGTT) at time of diagnosis

Alternative diagnostic markerElevated serum IGF-1 above age/gender adjusted normal range as provided by the physician's lab

Context of useRequired for diagnostic confirmation of acromegaly for coverage of IR and long-acting formulations

Adjunctive use for bleeding varices — Octreotide acetate coverage condition

Adjunctive use requirementOctreotide acetate is covered for bleeding esophageal varices only when used as an adjunct to endoscopic therapy

Associated diagnosisBleeding esophageal/gastroesophageal varices associated with liver disease

Revision History

2026-04-01retirement

Policy retired for Louisiana plan membership (membership disenrolled).

2025-06-01coverage_changeLatest

Policy language revised to state somatostatin analogs are unproven and not medically necessary for treating HIV-AIDS-related diarrhea and removed prior medical necessity criteria supporting that indication; applicable ICD-10 codes reformatted and certain codes (B20, R19.7) removed.

Policy Summary

PayerUnitedHealthcare

PolicySomatostatin Analogs (for Louisiana Only)

Policy CodePolicy CSLA2025D0036V

Change TypeCoverage stance updatedHIV-AIDS-related diarrhea removed as proven

Effective DateJun 1, 2025

Next Review DateN/A

Key ActionSubmit prior authorization with diagnostic confirmation and documentation of prior short‑acting response when requesting long‑acting somatostatin analogs.

SourceLink

On This Page

Persistent hyperinsulinemic hypoglycemia of infancy — long-term safety and role are not well established; unproven.

Prevention of postoperative complications following pancreatic surgery — evidence is mixed; routine use for non-malignant pancreatic surgery is not supported, though some trials suggest reduced perioperative complications in malignancy settings.

Short bowel syndrome — evidence is limited and requires further study; considered unproven for routine treatment.

Any indication not listed as proven in this policy is considered unproven due to lack of published clinical evidence of safety and/or efficacy.

Meta-analyses dividing trials by total octreotide dose showed benefit at >=0.5 mg

LimitationsInsufficient data to determine optimal route or timing despite dose-related findings

For Cushing's disease or other labeled indications: document diagnostic testing per prescribing information and specialty guidelines.

When long‑acting formulary requires, document prior effective and tolerated trial of the immediate‑release (IR) formulation before transitioning to LAR (e.g., Sandostatin LAR).

Documentation Required

Coverage Requires Alignment With FDA Indications

Use of somatostatin analogs must align with FDA‑labeled indications. Requests for use outside labeled indications should include supporting literature and will be reviewed for medical necessity; lack of an FDA‑indicated diagnosis may result in a denial.

Common labeled indications: acromegaly, carcinoid syndrome/GEP‑NET symptoms, VIPoma diarrhea, Cushing's disease (pasireotide), and long‑term maintenance when prior IR therapy demonstrated efficacy and tolerability.
Limitation of use statements (e.g., tumor size/growth effects not established) must be recognized in decision documentation.

Denial Risk

Bleeding Esophageal Varices — Adjunctive Use Requirement

When octreotide is requested for bleeding esophageal varices, it must be documented that the patient has esophageal variceal bleeding associated with liver disease and that octreotide will be administered as an adjunct to endoscopic therapy. Absence of endoscopic therapy or documentation that octreotide is not adjunctive may result in denial.

ICD‑10 examples: I85.01 (esophageal varices with bleeding) — ensure chart notes reflect contemporaneous endoscopic intervention.
Adjunctive use only; not a substitute for endoscopic management.

Billing Rule

Coding and Diagnosis Match Required

Ensure the billed HCPCS/J‑code matches the submitted diagnosis. A mismatch between the drug code and the supported ICD‑10 diagnosis may result in denial. Include the formulation (IR vs LAR/Depot), route (SC, IM, IV), dose, frequency, and evidence of prior response or tolerability where required.

Examples: J2353/J2354 for octreotide (depot and non‑depot forms), J1930/J1932 for lanreotide, J2502 for pasireotide LAR.
If submitting for LAR after IR trial, include documentation of IR dosing, duration, efficacy and tolerability.

Documentation Required

Acromegaly Diagnostic and Prior Therapy Documentation

For acromegaly specifically, include diagnostic confirmation and prior therapy details in the request: date and results of OGTT and/or IGF‑1 testing at diagnosis, prior surgical or radiotherapy interventions and outcomes, trials of dopamine agonists, and whether the patient is a surgical/radiation candidate.

Required diagnostics: serum GH nadir > 1 ng/mL after 2‑hour OGTT OR elevated age‑/sex‑adjusted IGF‑1 at diagnosis.
Document prior treatments: surgery date and operative report, radiotherapy dates and response, dopamine agonist agent, dose, duration, and response.

Documentation Required

Formulation, Route, and Prior Response

Support the requested formulation and route with clinical rationale and prior response/tolerability data. For long‑acting depot formulations, document whether an initial trial of the immediate‑release (IR) formulation demonstrated efficacy and tolerability when indicated by prescribing information.

If requesting Sandostatin LAR, document prior effective and tolerated use of immediate‑release Sandostatin injection unless clinical circumstances justify direct LAR initiation and are documented.
Specify route: Sandostatin LAR is IM (intragluteal) q4 weeks; Somatuline Depot and lanreotide are deep SC depot formulations.

Documentation Required

Biochemical Monitoring and Adverse Event Surveillance

Baseline and follow‑up biochemical monitoring and surveillance for adverse events must be documented for patients on pasireotide/pasireotide LAR and other somatostatin analogs. Include plans for glucose monitoring and liver function testing where clinically indicated.

Pasireotide/pasireotide LAR: document baseline fasting glucose/HbA1c and follow‑up schedule due to hyperglycemia risk.
For all SRLs: monitor GH and IGF‑1 at recommended intervals to assess biochemical control; document adverse events and management (e.g., gallbladder/biliary events, bradycardia, hepatic labs).

Documentation Required

Document FDA‑Indicated Diagnosis

Document the FDA‑indicated diagnosis being treated and reference the relevant product labeling or guideline support in the prior authorization. Include citations to updated prescribing information or clinical guidance when submitting off‑label requests for consideration.

State the specific FDA‑labeled indication (e.g., 'acromegaly — inadequate response to surgery', 'Cushing's disease — not a surgical candidate').
Attach relevant sections of the prescribing information showing indication and any limitations of use.

Documentation Required

Documentation Expectations and Operational Notes

Include complete clinical documentation consistent with UnitedHealthcare documentation expectations: diagnostic test results, prior treatment history and responses, justification for chosen agent and formulation, monitoring plan, and citations to current clinical evidence or prescribing information. Incomplete documentation may delay review or lead to denial.

Reference recent prescribing information (e.g., Somatuline, Signifor, Lanreotide Injection) and applicable guidelines (Endocrine Society, Pituitary Society) when relevant.
Requests for unproven indications (e.g., HIV‑AIDS‑related diarrhea) are not supported by this policy and may be denied.

Step Therapy

Guideline‑Recommended Therapeutic Sequencing and Step/Add‑On Considerations

Follow guideline‑recommended therapeutic sequencing when describing treatment history and future plans. Document whether somatostatin analogs or pegvisomant were used as initial adjuvant medical therapy, and describe any stepwise additions (e.g., add pegvisomant or cabergoline for inadequate response).

If proposing combination therapy (SRL + pegvisomant or pasireotide + pegvisomant), provide rationale, prior dosing, and monitoring plan; note that pasireotide combinations carry increased hyperglycemia risk.
State whether preoperative SRL use was considered per guidelines in patients with severe comorbidities.

inv-72: Acromegaly initial therapy — Guideline-recommended initial medical therapy in acromegaly

Guideline-recommended initial medical therapy in acromegaly

Initial adjuvant medical therapy: Somatostatin analogs (e.g., octreotide, lanreotide) or pegvisomant are recommended as initial adjuvant medical therapy for patients with significant acromegaly when surgery is not curative or feasible; choice is individualized based on comorbidities and surgical candidacy.

Endocrine Society and Pituitary Society guideline-based recommendations.

inv-73: Initial medical therapy — Initial medical therapy considerations from guideline updates

Initial medical therapy considerations from guideline updates

Initial adjuvant medical therapy: Guidelines note preoperative use of SRLs is discretionary to reduce surgical risk from severe comorbidities; somatostatin analogs or pegvisomant may be used as initial medical therapy depending on individual patient factors.

Considerations include age, tumor MRI characteristics, comorbidities, and potential for extended dosing intervals in select patients.

UFC <= ULN or documented clinical benefit

Baseline and ongoing glucose monitoring recommended; watch for early hyperglycemia-related adverse events.

inv-76: Continuation/maintenance — Long-term maintenance use per product labeling

Long-term maintenance use per product labeling

Long-term maintenance for acromegaly: Sandostatin LAR Depot, Somatuline Depot, and Lanreotide Injection are indicated for long-term maintenance in acromegalic patients who had an adequate trial with short-acting formulation or had inadequate response to or cannot be treated with surgery/radiotherapy; continue per labeling and monitor biochemical targets (GH and IGF-1).

Document prior trial and ongoing biochemical response (e.g., GH and IGF-1 targets).

Long‑acting depot injections are administered in outpatient/clinic settings per product labeling; immediate‑release/short‑acting formulations are used for titration or peri‑conception management as noted in guidance.

Somatuline Depot and Lanreotide Injection are prolonged‑release formulations for deep subcutaneous injection and are used per labeling (chunks 23, 65–66).

Denial riskAbsence of adjunctive endoscopic therapy documentation may trigger claim denial

Sandostatin LAR

Product descriptionSandostatin LAR is a long-acting intramuscular octreotide formulation designed for intragluteal injection once every 4 weeks and must be administered under physician supervision

Indication prerequisiteIndicated for patients in whom initial treatment with short-acting Sandostatin injection has been shown to be effective and tolerated

Route/frequencyIntramuscular (intragluteal) injection every 4 weeks

Signifor / Signifor LAR

Agent classPasireotide (Signifor / Signifor LAR) — somatostatin analog with high affinity for SSTR5

Clinical useUsed in Cushing's disease where corticotroph tumors frequently overexpress SSTR5 and for some patients with acromegaly

Safety noteAssociated with frequent hyperglycemia-related adverse events requiring monitoring and management

Somatuline Depot / Lanreotide Injection

FormulationsSomatuline Depot and Lanreotide Injection are long-acting lanreotide formulations for deep subcutaneous injection

Therapeutic effectReduce growth hormone (GH) and IGF-1 levels in acromegaly

AdministrationProlonged-release, deep subcutaneous injection with dosing per product labeling (typically every 4 weeks)

GH < 2.5 µg/L and age-adjusted normalized IGF-1

Biochemical control targetGH < 2.5 µg/L and age-adjusted normalized IGF-1 as common biochemical control in acromegaly

ContextUsed as treatment goal to document adequate response for continuation or step-therapy decisions

Source guidanceReferenced in guideline statements and trial endpoints for acromegaly management

Reduction in mean urinary free cortisol to ≤ upper limit of normal

Biochemical response endpointReduction in mean urinary free cortisol to ≤ upper limit of normal (UFC ≤ ULN)

Clinical contextPrimary efficacy endpoint used in trials of pasireotide for Cushing's disease and for continuation decisions

Monitoring implicationRequires baseline and follow-up UFC measurements and surveillance for hyperglycemia

SRL (somatostatin receptor ligand)

DefinitionSRL (somatostatin receptor ligand) — injectable long-acting agents such as octreotide, lanreotide, and pasireotide

Primary effectsUsed to lower GH and IGF-1 in acromegaly and to control hormone-mediated secretory syndromes

FormulationsAvailable as immediate-release and long-acting depot formulations

Pegvisomant

MechanismPegvisomant is a growth hormone receptor antagonist that normalizes IGF-1 in many patients with acromegaly

OutcomesLong-term data (ACROSTUDY) show ~73% biochemical control at 10 years

Role in therapyUsed alone or added when inadequate response to SRLs; improves glucose metabolism in patients with diabetes

Somatostatin analogs

Class definitionSomatostatin analogs — pharmacologic class including octreotide, lanreotide, and pasireotide used for endocrine tumors, acromegaly, Cushing's disease, and control of GI secretions/complications

Formulations includedImmediate-release and long-acting depot (LAR/Depot) formulations across agents

Clinical usesIndications include acromegaly, carcinoid syndrome/VIPomas, malignant bowel obstruction, variceal bleeding adjunctive therapy, and select other indications per evidence summaries